GHK-Cu Copper Peptide: What the Published Research Reports

GHK (glycyl-L-histidyl-L-lysine) is described in the literature as a naturally occurring tripeptide detected in human serum, with reported average serum levels of approximately 200 ng/ml at age 20 declining to approximately 80 ng/ml by age 60 [1]. The peptide has been characterised as a high-affinity copper(II) ligand that forms the chelate GHK-Cu [1]. An earlier narrative review catalogued the processes attributed to GHK and GHK-Cu in tissue remodelling research, including chemoattraction of repair cells, modulation of inflammatory mediators, changes in synthesis of collagen, elastin, metalloproteinases and several growth factors, and proliferation of fibroblasts and keratinocytes, drawing on a mixture of in vitro, animal and human skin studies [2]. A separate review proposed GHK and GHK-Cu as candidates for investigation in oxidative stress and age-associated neurodegeneration research, citing reported antioxidant and anti-inflammatory activity and effects on gene expression [3]. A substantial part of the GHK-Cu literature is structural and physicochemical. X-ray and solution-phase spectroscopic work reported that Cu(II)-GHK is dimeric in the solid state but forms a monomeric complex in solution with three nitrogen donors (amine, amidyl and imidazole nitrogen), and that the complex could be reduced to Cu(I) at around -0.62 V with subsequent release of the copper ion, in contrast to Cu(II)-DAHK; this work was conducted in vitro using purified complexes [4]. Computational studies using ligand field molecular mechanics, density functional theory and semi-empirical methods modelled Cu(II) binding to GHK and reported a stable 3N1O equatorial coordination over a 100 ps molecular dynamics trajectory, with a more fluxional apical carboxylate contact [5]. Another in vitro study reported that cis-urocanic acid also coordinates Cu(II) and that GHK and cis-urocanic acid together form a ternary Cu(II) complex, which the authors proposed may co-occur in skin and plasma [6]. An older electron spin resonance study using Ehrlich ascites cells reported that Cu-GHK did not form ESR-detectable adducts with glutathione or with the cells, consistent with poor cellular uptake of the intact complex, and that a Cu(His)2 species appeared to form on interaction with cells [7]. In cell-culture and reconstructed-skin work, copper-free GHK was reported to increase proliferation of cultured normal human keratinocytes, and in skin-equivalent models to alter basal cell morphology, increase α6 and β1 integrin staining along the basement membrane, and increase numbers of p63- and PCNA-positive cells relative to untreated controls; the authors reported these in vitro effects as similar to those previously described for copper-GHK [8]. Animal and invertebrate models make up much of the remaining primary literature. In a bleomycin-induced pulmonary fibrosis model in C57BL/6J mice, intraperitoneal GHK-Cu was reported to reduce inflammatory and fibrotic histological changes, lower TNF-α and IL-6 and myeloperoxidase activity in bronchoalveolar lavage fluid, reduce collagen deposition, and alter Nrf2, NF-κB and TGFβ1/Smad2/3 signalling markers [9]. In zebrafish larvae challenged with copper sulfate or lipopolysaccharide, GHK-Cu was reported to reduce neutrophil and macrophage migration, lower tnf-a, il-1β and il6 expression while raising il-10, reduce nitric oxide and reactive oxygen species, increase superoxide dismutase activity, and downregulate the JAK1 pathway [10]. In Caenorhabditis elegans, GHK-Cu was reported to extend lifespan and to modify aging-related phenotypes including oxidative and thermal stress resistance, motility, pharyngeal pumping and lipofuscin accumulation, with reported changes in mitochondrial membrane potential, drp-1 and fzo-1 expression, ATP biosynthesis, and DAF-16 and SKN-1 pathway target genes such as sod-3, gst-4 and gcs-1 [11]. A review also noted preliminary observations that GHK partially reversed cognitive impairment measures in aging mice through anti-inflammatory and epigenetic pathways [1]. Much recent primary work places GHK-Cu inside biomaterials rather than studying it alone. An injectable hydroxyapatite microsphere filler loaded with GHK-Cu showed approximately seven-day sustained release in vitro and, in LPS-induced inflammation models studied both in vitro and in vivo, was reported to lower inflammatory factor and reactive oxygen species levels, raise superoxide dismutase activity, and increase collagen deposition on histological staining [12]. A self-healing hydrogel made from oxidised konjac glucomannan and egg white loaded with GHK-Cu was evaluated as a dressing in an infected wound model with reported antibacterial, anti-inflammatory, hemostatic and neovascularisation-related outcomes [13]. A glucose-oxidase-loaded hydrogel incorporating GHK-Cu was reported to drive a cascade in which generated hydrogen peroxide is decomposed by copper ions in a catalase-like reaction, with antibacterial, antioxidant and angiogenesis-related outcomes reported in an infected diabetic wound model [14]. A stimuli-responsive polyaspartic acid/AMPS/alginate gel was characterised for GHK-Cu encapsulation (55.26% efficiency, 51.84% release at 24 h for the EGDMA-crosslinked polymer) and then assessed in vivo for wound closure, histopathology, biochemistry and toxicity [15]. GHK-Cu has also been loaded into mesoporous silica nanoparticle–chitosan coatings deposited on titanium, where copper release was reported to be pH-dependent and the coatings were characterised in vitro for bacterial adhesion and cytocompatibility [16]. Delivery across skin remains an open analytical question in this literature. A review concluded that GHK-Cu is relatively hydrophilic with limited permeation through the stratum corneum, that liposomal encapsulation has been proposed as a way to change that, and that transport of liposome-encapsulated GHK-Cu has received little methodological attention [17]. A related in vitro analytical study applied capillary electrophoresis coupled to inductively coupled plasma tandem mass spectrometry to confirm liposome formation and quantify encapsulated GHK-Cu by monitoring copper and phosphorus signals [18]. Two recent reviews addressed GHK-Cu in the context of peptides marketed for musculoskeletal and athletic applications. A narrative review grouped GHK-Cu with other approved and unapproved peptides and stated that many unapproved peptides show tissue repair or metabolic outcomes in animal models while rigorous human safety data are scarce, and that products sold outside regulatory oversight carry potential for harm [19]. A PRISMA-guided scoping review of six emerging peptides including GHK-Cu found that 67% of identified publications used preclinical animal models, most commonly rats; human clinical studies were limited to a handful of investigations, most lacking robust controls or rigorous designs, with heterogeneous results and modest findings at best, leading the authors to conclude that claimed benefits remain unsubstantiated by current human trials [20].